Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.

about

Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells

P2860

Q59127433-4C050738-706A-48FD-82E1-1E4DBDB49F22

P2860

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.

Item

http://www.wikidata.org/entity/Q47105720

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Inhibition of PI3K/Akt/mTOR ov ...... breast cancer cell line HCC38.

@en

Inhibition of PI3K/Akt/mTOR ov ...... breast cancer cell line HCC38.

@nl

type

Item

label

Inhibition of PI3K/Akt/mTOR ov ...... breast cancer cell line HCC38.

@en

Inhibition of PI3K/Akt/mTOR ov ...... breast cancer cell line HCC38.

@nl

prefLabel

Inhibition of PI3K/Akt/mTOR ov ...... breast cancer cell line HCC38.

@en

Inhibition of PI3K/Akt/mTOR ov ...... breast cancer cell line HCC38.

@nl

P1476

Inhibition of PI3K/Akt/mTOR ov ...... breast cancer cell line HCC38.

@en

P2093

Alexandra Hamacher

http://www.w3.org/2001/XMLSchema#string

Katharina Gohr

http://www.w3.org/2001/XMLSchema#string

Laura H Engelke

http://www.w3.org/2001/XMLSchema#string

Matthias U Kassack

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Triple-Negative Breast Cancer

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Drug combination studies and their synergy quantification using the Chou-Talalay method

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

P2888

s12885-017-3695-5

P304

711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3695-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092517239

http://www.w3.org/2001/XMLSchema#string

P698

29100507

http://www.w3.org/2001/XMLSchema#string

P932

5670521

http://www.w3.org/2001/XMLSchema#string

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.

about

P2860

P2860

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P6179

P698

P932